ERRATUM article

Front. Med., 29 April 2025

Sec. Regulatory Science

Volume 12 - 2025 | https://doi.org/10.3389/fmed.2025.1611335

This article is part of the Research TopicPaediatric Drug DevelopmentView all 7 articles

Erratum: Requirements and special considerations for drug trials with children across six jurisdictions: 2. Ethics review in the regulatory approval process

This article is an erratum on:

  1. Requirements and Special Considerations for Drug Trials with Children Across Six Jurisdictions: 2. Ethics Review in the Regulatory Approval Process

    1. Read original article
Frontiers Production Office Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Requirements and special considerations for drug trials with children across six jurisdictions: 2. Ethics review in the regulatory approval process

by Stewart, B., Lepola, P., Egger, G. F., Ali, F., Allen, A. J., Croker, A. K., Davidson, A. J., Dicks, P., Faust, S. N., Green, D., Hovinga, C., Klein, A. V., Langham, R., Nakamura, H., Pioppo, L., Ramroop, S., Sakiyama, M., Sanchez Vigil de la Villa, I., Sato, J., Snyder, D. L., Turner, M. A., Zaidi, S., Zimmerman, K., and Lacaze-Masmonteil, T. (2025). Front. Med. 12:1539787. doi: 10.3389/fmed.2025.1539787

Due to a production error, there was an error in the Conflict of Interest Statement. Instead of “The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.” It should have read “DS is currently employed by company WCG Clinical.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The publisher apologizes for this mistake.

The original article has been updated.

Keywords: pediatrics, clinical trials, regulatory science, research ethics review, research ethics committee, institutional review board

Citation: Frontiers Production Office (2025) Erratum: Requirements and special considerations for drug trials with children across six jurisdictions: 2. Ethics review in the regulatory approval process. Front. Med. 12:1611335. doi: 10.3389/fmed.2025.1611335

Received: 14 April 2025; Accepted: 14 April 2025;
Published: 29 April 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.